Coeptis Therapeutics (ZSQR) Stock Price, News & Analysis

Company Overview

Coeptis Therapeutics Holdings, Inc. is a biotechnology company focused on developing cell therapy platforms and other treatments for cancer and autoimmune diseases. The company’s research is centered on approaches intended to improve the targeting, flexibility and potential effectiveness of immune-cell therapies.

Its principal platform, SNAP-CAR, is designed to support adaptable chimeric antigen receptor (CAR) cell therapies that can target different disease-associated antigens. Coeptis has also pursued related therapeutic programs through collaborations and licensing arrangements, including research involving natural killer (NK) cells and other immune-based treatment technologies.

Coeptis is based in the United States and has focused primarily on developing its pipeline through strategic partnerships and biotechnology collaborations. The company’s programs remain investigational and are subject to preclinical and clinical development requirements before any potential commercialization.

Key Stats

• Today's Range: $4.93 to $5.78
• 50-Day Range: $2.29 to $5.66
• 52-Week Range: $2.11 to $21.41
• Volume: 288,350 shs
• Average Volume: 295,705 shs
• Market Capitalization: $285.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Coeptis Therapeutics Stock Analysis - MarketRank™

Coeptis Therapeutics scored higher than 12% of companies evaluated by MarketBeat, and ranked 547th out of 596 stocks in the technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Coeptis Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Coeptis Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Coeptis Therapeutics is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Coeptis Therapeutics is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Coeptis Therapeutics has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.30% of the float of Coeptis Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Coeptis Therapeutics has a short interest ratio ("days to cover") of 9.45.

Change versus previous month

Short interest in Coeptis Therapeutics has recently increased by 10.29%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Coeptis Therapeutics does not currently pay a dividend.

Dividend Growth

Coeptis Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Coeptis Therapeutics has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Technology companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Coeptis Therapeutics this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Coeptis Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.0 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $3,920.00 in company stock, which represents 0.0014% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Coeptis Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,920.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

24.25% of the stock of Coeptis Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

13.88% of the stock of Coeptis Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Technology
• Industry: Software
• Sub-Industry: Application Software
• Current Symbol: NASDAQ:ZSQR
• Previous Symbol: NASDAQ:COEP
• CIK: 1759186
• Web: ir.zsquaredinc.com
• Phone: (954) 400-9994
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.92 million
• Net Margins: -773.72%
• Pretax Margin: -953.59%
• Return on Equity: -49.45%
• Return on Assets: -46.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.66
• Quick Ratio: 7.66

Sales & Book Value

• Annual Sales: $1.36 million
• Price / Sales: 213.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.63 per share
• Price / Book: 2.08

Miscellaneous

• Outstanding Shares: 53,000,000
• Free Float: 40,148,000
• Market Cap: $289.91 million
• Optionable: Not Optionable
• Beta: -0.29